Evolution of Novel Therapies in the Treatment of Acute Lymphoblastic Leukemia

In this segment, “Evolution of Novel Therapies in the Treatment of Acute Lymphoblastic Leukemia”, Elias Jabbour, MD, and Bijal Shah, MD, MS, highlight novel and emerging therapies and combinations for the treatment of ALL.

Much progress has been made in ALL therapeutics, along with dramatic improvements in patient outcomes. The evolution of ALL treatment is moving at a rapid pace, as we now have choices among many highly effective new agents and combinations (chemotherapy regimens, TKI and immunotherapy combinations, CAR T-cell therapy). Ongoing research seeks to better define optimal sequencing and combination of these agents.